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Of all the animals so far studied, man is the only one known to be incapable of healing 
prosthetic vascular grafts with its own natural endothelium. Consequently there has 
been considerable effort in the 30 or so years since the first prosthetic grafts became 
available either to find truly nonthrombogenic artificial materials or to enhance the 
body’s own natural healing processes in order to provide blood-compatible devices. It 
has been known from the days of the earliest prosthetic grafts that the fibrin-platelet 
coagulum that typically lines them is an adequate surface only for grafts of 8 mm i.d. 
or greater. Unfortunately, the need for smaller prostheses is equal to or greater than 
that for the large. In the early days, emphasis in graft development was focused on 
different materials, such as nylon, Dacron, Teflon, tanned bovine carotid arteries, or 
umbilical veins as conduits. 
Paralleling the work with prosthetic vessels was the development of the artificial 
heart and the desire to provide blood-compatible linings for these devices. The idea of 
cell or tissue fragment seeding of prostheses in order to provide pseudointimal linings 
originated because of its applicability to artificial hearts (see ref. 2 for a review of this 
early work). Our own work in this area began with artificial hearts as well, under the 
auspices of the National Heart, Lung, and Blood Institute and the Artificial Heart 
Program. At that time the emphasis was on developing microfiber substrates upon 
which to grow pseudointimal linings and on finding a cell or tissue type that would 
provide a blood-compatible surface. In order to develop these materials and methods 
the prosthetic devices were fabricated into nonporous urethane tubes lined with a 
microfiber scaffold and of a size that could be tested by interposition in the abdominal 
aorta of a dog (FIG. 1). The cells were introduced into the prostheses and cultivated in 
vitro until a pseudointima developed.” The progress was slow; materials were not very 
cell compatible, and the cells that were easily grown in vitro were thrombogenic. 
However, in the late 1970s several developments occurred that made cell-lined 
vascular grafts a practical reality. First, we and other groups of investigators finally 
learned how to isolate and grow adult endothelial cells. Second, we switched from the 
troublesome microfiber grafts to commercially available vascular prostheses (FIG. 2). 
Third, a new group of investigators4 discovered that scrapings from the intima of 
cutaneous veins, seeded into grafts in clotted blood and then immediately implanted 
into dogs, would produce endothelial linings in these vessels. With these developments 
research on endothelial cell seeding greatly increased. In the last few years endothelial 
cell seeding techniques have developed rapidly to the point where clinical reports of 
success with the method are beginning to appear’ (for a complete review, see refs. 6 and 
7). In the following pages we will briefly describe the method and the current status of 
research in this area. This presentation is not meant to be exhaustive, but to highlight 
some of the more important observations as well as questions still to be answered. 
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FIGURE 1. (A) Urethane tube lined with nonwoven polypropylene microfiber like that used in 
early seeding experiments (shown actual size). (B) SEM micrograph of microfiber lining; 
magnification: lOOOx . 
FIGURE 2. (A) Surface of a clinically used knitted Dacron, velour, crimped graft; magnification: 
25 x. (B) Surface of expanded Teflon (ePTFE) graft at the same magnification as A; note the 
relative smoothness. 
THE METHOD 
Endothelial Cell Isolation 
Most commonly, endothelial cells (EC) are isolated from subcutaneous veins using 
proteolytic enzymes. In dogs external jugular veins are isolated, removed, and everted 
over stainless steel rods' in order to prevent exposure of nonendothelial cells to the 
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FIGURE 3. Phase contrast micrograph 
typical canine venous endothelial cells 
tissue culture; magnification: 300x. 
I of 
in 
enzymes. After washing in calcium- and magnesium-free Hanks’ balanced salt 
solution (CMF-HBSS), the veins are incubated successively in 0.1% trypsin-0.125% 
EDTA, pH 8, and 0.5% collagenase (CLS type 11), pH 8, each for 10 minutes at  37OC. 
The rods are then spun in Mediums199 (M199) to dislodge the EC and the exfoliated 
cells washed in M199 in preparation for graft seeding or tissue culture (FIG. 3). 
A good cell harvest will yield 1.0-1.5 x lo6 cells from a 10 x 0.5 cm segment of vein. 
Endothelial Cell Seeding 
The EC, either immediately after isolation or after in vitro cultivation, are seeded 
into vascular grafts which have been precoated with autologous blood or some other 
adhesive, such as fibronectin.”’ With Dacron grafts, which are usually porous, the 
cells are suspended in 0.5 ml of M199 and mixed with 10 to 15 mi of whole blood, the 
FIGURE 4. Photomicrograph 
of a Dacron graft seeded with 
cells; EC, endothelial cells; G, 
F, fibrin. Magnification: 600x 
of a section 
endothelial 
graft fiber; 
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distal end of the graft clamped, and the cell-blood mixture injected into the graft, as for 
preclotting. The blood is forced through the graft wall filtering out the endothelial 
cells, which are thus seeded into the interstices (FIG. 4).’.12 With grafts that are 
nonporous to blood, such as expanded Teflon (ePTFE), the cells are mixed with a small 
amount of tissue culture medium, injected into the graft, which has been pretreated 
with blood or some other adhesive, the ends clamped, and the graft left to sit 
horizontally.” Periodic rotation of the graft during the seeding process allows for even 
distribution of cells. If blood has been used in the seeding process, the grafts are flushed 
with a small amount of heparinized blood.’’ The grafts are implanted in the 
experimental animal using standard surgical procedures, with care taken to prevent 
dessication. In experiments using E C  that have been cultivated prior to seeding,’ the 
procedures are the same following trypsinization of the culture flasks to obtain a cell 
suspension. As an alternative, grafts may be cultivated in vitro after seeding in order to 
obtain a confluent endothelial lining prior to implantation. The methods used are 
similar to those described in ref. 2. This procedure may be more useful for grafts placed 
in small vessels or in the venous c i rc~la t ion , ’~  which with low flow are more susceptible 
to thrombosis. 
A variety of graft types have been used for EC seeding studies, such as knitted 
Dacron, with or without velour surface, crimped or noncrimped, externally supported 
or not. Expanded Teflon grafts are seeded equally well, whether of standard or greater 
than standard porosity. Sites for implantation and testing of the seeded grafts have 
included: thoracoabdominal bypass grafts, infrarenal, aortoiliac, iliac, iliofemoral, 
femoral, and carotid arteries as well as inferior vena cava. Small diameter grafts (<6 
mm i.d.), whether seeded or not, have usually required pharmacological intervention to 
maintain early patency.I4 
RESULTS 
Endothelialization (healing) of the graft surface proceeds rapidly after graft 
implantation, the rate depending upon the number of cells that are seeded and how 
tightly adherent they are to the graft surface. Small clusters of EC, appearing much 
like colonies of cells in a tissue culture flask, are visible on the graft surface between 1 
and 4 days (FIGS. 5 and 6).12 These cells grow rapidly and by 14 days as much as 75% of 
the graft surface is covered with endothelium (FIG. 7). Within the next month the 
remainder of the surface becomes covered with EC (FIG. 8). Initially this neointima is 
a monolayer of cells (FIG. 9), but with time subendothelial smooth muscle cells appear 
to form a layer of variable thickness (FIG. 10) depending upon the graft type and 
length of implantation.” The lining cells display all of the characteristics of endothe- 
lium, including cobblestone morphology and tight intercellular  junction^,'^ Weibel- 
Palade bodies,I6 the presence of factor-VIII-related antigen” (FIG. 1 l) ,  nonthrombo- 
genicity,’* and lack of platelet adhesion and production of prostacyclin (PGI2).I9 In 
addition, platelet serotonin levels” and platelet survival return to normal significantly 
faster in seeded grafts.20,21 
Nonseeded grafts, in contrast, become lined with a fibrin-platelet coagulum shortly 
after implantation that is frequently several hundred micrometers in thickness and 
which may persist indefinitely (FIG. 12). Eventually most nonseeded porous grafts in 
experimental animals heal from cells growing into the graft as pannus from the natural 
vessel, from tissue surrounding the graft, or perhaps from circulating EC sponta- 
neously seeded from the bloodstream. 
These results have been duplicated in both large (>6 mm i.d.) and small diameter 
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FIGURE 5. SEM micrograph of a clu 
of EC on a Dacron graft shortly a 
implantation; magnification: 400x. 
ster 
fter 
FIGURE 6. Light micrograph of a seeded 
Dacron graft 4 days after implantation; 
the cells have begun to form a monolayer 
on the surface: magnification: 200x. 
( ~ 6  mm i.d.) arterial grafts as well as venous grafts. In addition, EC seeding has been 
shown to be effective in man’ as well as baboonsz2 and rhesus monkey.23 
DISCUSSION 
Cell Sources 
As pointed out earlier, a wide variety of tissue sources were initially evaluated2 in 
attempts to find a cell type that was readily available, easily isolated, and that 
possessed the necessary nonthrombogenic characteristics. The obvious choice for lining 
grafts was the endothelial cell, but routine methods for obtaining large quantities of 
cells necessary for seeding had not been developed. The publication of a routine method 
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FIGURE 7. Light micrograph of a seeded Dacron graft 2 weeks postimplantation; the EC lining 
and subjacent smooth muscle are well developed; magnification: lOOx. 
FIGURE 8. SEM micrograph of the cut edge of a seeded Dacron graft 8 weeks after 
implantation; magnification: 300x. 
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FIGURE 9. Light micrograph of a seeded a FTFE graft 1 month after implantation; the EC are 
in a monolayer; magnification: 300x. 
for obtaining EC from human umbilical veins by Jaffe et aLZ4 spurred interest in this 
cell type. With the demonstration that the method could be modified to harvest bovine 
aortic EC?’ two models were available and in vitro research flourished. While 
adequate to harvest embryonic and bovine EC, these methods worked only poorly on 
adult vessels and the adult EC derived were difficult to grow in culture. 
In addition, to prevent rejection, autologous EC were needed for seeding the grafts. 
Over the next few years the above methods were successfully modified to isolate adult 
EC from several different types of animals and vessels, including: human iliac arteries; 
human and bovine pulmonary arteries and veins; porcine aortas, inferior vena cavas, 
and pulmonary veins; rabbit aortas and marginal ear vessels; guinea pig aortas and 
FIGURE 10. Light micrograph of a seeded 
Dacron graft at 1 year. The original mono- 
layer lining has thickened considerably due 
to growth of the underlying smooth muscle 
cells; magnification: 150 x . 
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FIGURE 11. Fluorescence micrograph of 
a seeded Dacron graft stained for factor- 
VIII-related antigen and photographed by 
epi-illumination. The white dots are clus- 
ters of stained factor VIII in individual 
cells; magnification: lOOx. 
FIGURE 12. (A) SEM micrograph of a nonseeded Dacron graft 1 month after implantation, and 
(B) light micrograph of a similar graft 6 months after implantation. The surface of both is 
composed of a fibrin platelet coagulum. Magnifications: (A) 8 O O x ;  (B) 15Ox. 
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portal veins; and canine jugular veins and aortas (see ref. 26 for further discussion). Of 
most importance for graft seeding purposes were methods that could be applied to 
adult subcutaneous veins that are expendable and potentially useful for clinical 
application of the seeding technique. Most experiments involving graft seeding have 
been done with canine jugular veins, a model for human saphenous vein, which is the 
current choice for clinical application. 
While subcutaneous veins such as saphenous can provide large numbers of cells 
(potentially 1 x los cells/cm2 of vein surface), microvascular EC from adipose tissue 
is even more abundant (potentially 1 x 10" cells per gram of fat) as well as expendable. 
With this quantity of cells it may be possible to seed enough cells at  the time of 
implantation to line the graft completely.27p2" While abundant cells are available from 
microvasculature, there is a possibility of considerable contamination of the isolates 
with perivascular or smooth muscle cells. The effect of these cells on the ultimate fate 
of a seeded graft is unknown. 
Recently, mesothelial cells derived from omentum have been used for graft seeding 
and have been found to produce an intimal lining similar to endothe l i~m.~~ These cells 
produce large amounts of PG12, possess fibrinolytic activity, and do not adhere 
platelets. Like microvasculature from fat, mesothelial cells are abundant and easily 
isolated, thus sparing subcutaneous veins for possible coronary bypass if necessary. No 
long-term studies of grafts seeded with these cells have been done, however. 
It has been reported that grafts seeded with nonautologous EC give rise to 
endothelial linings.3G32 Considering the known antigenic nature of EC, it seems 
unlikely that the cells lining these grafts could be from the donor. Grafts were 
examined only at 2 months postimplantation, more than long enough for spontaneous 
healing to occur. 
Endothelium has been observed in the middle of nonseeded grafts used as controls 
as early as 2 weeks.12 Until it has been proved that the cells lining these grafts were 
actually from the donor, these reports must be viewed with some skepticism. It seems 
possible, however, that something in the inoculum, such as growth factors from the 
donor cells (before their loss), could have hastened healing. 
Cell Zsolation 
The earliest and most common methods of isolating EC have been through the use 
of proteolytic enzymes that attack either the cell junctions or substrate to which the 
cells are attached. Jaffe et dZ4 used collagenase injected into cannulated umbilical 
veins. While this works well for easily detached EC, it works less well for adult vessels, 
particularly canine. Rapid perfusion of fluids through the vessel helps in removing 
cells, but for dog vessels we prefer a method that offers even more agitation or shearing 
forces to dislodge cells.' This is accomplished by everting the vein over a stainless steel 
rod, suturing it in place, and then after incubation in the enzyme solutions, spinning it 
with a stirring motor while submerged in M199. Although collagenase has been widely 
used experimentally, there has been some concern raised about its clinical use since it 
may contain undesirable DNases. 
Other enzymes, such as trypsin without EDTA, chymotrypsin, pronase, and 
elastase have been used with less success. The neutral protease Dispase (grades I or 11) 
has been suggested by the manufacturer to be good for cell isolation. Thilo et used 
it for umbilical vein cells with good results. 
Mechanical removal of EC from vessels with steel wool pledgets was used by 
Herring et al.' in their early seeding studies. Most likely smooth muscle cells from the 
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tunica media of the veins were removed as well, however, and this method would 
appear to give mixtures of cell types that may be undesirable. Ryan” has long 
advocated the use of mechanical removal of EC either through gentle scraping of the 
vessels or by using polystyrene beads. 
While these mechanical methods preserve cell surface coatings and receptors on 
EC, their use does not seem practical for EC seeding. 
The isolation of microvascular endothelium from fat requires collagenase digestion 
of minced tissue and a series of filtering and sedimentation steps to get capillary 
fragments.” While the method produces large quantities of cells, the procedure is 
somewhat more lengthy than that used for large vessel endotheiium; mixtures of EC, 
pericytes, and smooth muscle are likely and this may therefore be less desirable. 
Mesothelium from omentum, in contrast, was removed by collagenase digestion and 
can be done quite rapidly, but may have the same contamination problems. 
Seeding of Crafts 
Application of EC to the grafts has been done in a variety of ways. In their first 
report of successful endothelial cell seeding Herring et mixed the cells with whole 
blood that was used to preclot the grafts. 
Subsequently several other investigators have used this method on both large-and 
small-diameter Dacron and ePTFE grafts. 
When using this method with Dacron grafts, the cells are trapped in the interstices 
of the graft wall and 50-75% of the cells remain in the graft when blood flow is 
r e~ to red .~~ . ’~  Grafts of ePTFE are not usually preclotted, since they are relatively 
impermeable to blood, but introducing cells into the grafts using blood as an initial 
adhesive produces a healing in the grafts at a rate comparable to that of Dacron even 
though only 3 4 %  of the initial inoculum remains after blood flow is restored.” Since 
the rate of healing depends upon the number of cells in the graft per unit area that 
contributes to the endothelial lining and large numbers of cells may not be available for 
clinical seeding, it is important that all of the cells introduced into the graft remain. 
To accomplish this, two things are necessary: (1) to get the cells to the graft 
surface, and (2) to provide a suitable substrate to which the cells can tenaciously 
attach. Simple settling of cells on the surface by gravity is the simplest method, but is 
slow and even distribution is difficult to obtain. Introducing cells in blood and trapping 
them in a clot also works, but many cells are lost when blood flow is restored since the 
cells are not really attached to the graft itself. Forcing the cells against the graft 
surface by centrifugal force quickly provides almost 100% cell a t ta~hment ,~  but is 
somewhat impractical for long small-diameter or bifurcated grafts. Although much 
work has been done on cell adhesives for grafts, little work has been done on getting the 
cells directly on the surface and evenly distributed. 
Providing the best surface for cell attachment has been a goal since the earliest 
days of seeding.2 Clearly the reason that recent EC seeding on standard Dacron4,’ and 
ePTFE15 is successful is that the cells do not come directly in contact with the graft, but 
with blood proteins coating the graft. This has been shown in studies on EC adhesion 
with Dacron2’ and ePTFE,” where bare grafts gave poor adhesion while coatings of 
collagens, or pla~ma,~’ or fibronectin” greatly increased cell retention. In addition, the 
DNA content of EC attached to bare ePTFE decreased with time, indicating a lack of 
cell pr~liferation.~~ On ePTFE grafts coated with glucosaminoglycan-keratin cell 
adhesion was promoted, but like the naked graft cells showed minimal proliferation?’ 
S e n t i ~ s i ~ ~  reported that EC seeded on ePTFE coated with fibronectin and type I 
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collagen gave good growth and were highly resistant to shear in an in vitro shunt. In in 
vivo studies, Koeveker et aL4' found that fibrin glue, used to make grafts impermeable, 
provided a poorer surface for EC healing than did whole blood coatings. 
Extracellular matrices similar to those underlying natural endothelium would seem 
intuitively to be the best graft  coating^.'^ Dacron grafts coated with a combination of 
interstitial collagens (types I/III) and amnion-derived basement membrane (collagen 
type IV) gave firm adherence to 70% of seeded cells within 30 min. Interestingly, grafts 
treated with platelet-rich plasma alone gave similar attachment in only 10 min. 
In in vivo studies with ePTFE grafts, Ramalanjoana et al." found that 47% of EC 
attached to grafts coated with fibronectin in comparison to 19.8% on grafts in which 
cells were seeded in blood. When implanted in the carotid artery, fibronectin did not 
prevent cell loss within the first 30 min, but at 24 hours six times as many cells were 
present in the coated compared to the noncoated grafts (21.3 vs. 3.4%). Despite the 
increase in cell adhesion by coatings with extracellular matrix proteins, the loss of 80% 
of the seeded cells leaves much room for improvement, and much work still needs to be 
done on both coatings and seeding methods. 
If all of the seeded cells remained attached to the grafts they would heal in a matter 
of days instead of weeks as is now the case. 
There is no agreement on the best physical design of a graft for EC seeding, with 
some6 advocating less porous and others4' more porous grafts. There does seem to be 
general agreement that a relatively smooth surface is better!3 The graft material 
seems to be less important than the surface coating. With current knowledge of 
extracellular matrix proteins and growth factors, it should be possible in the near 
future to design a graft ideally suited to endothelial cell seeding. 
The addition of EC growth factors to graft surfaces to enhance healing may also be 
desirable. Greisler et a1.- have recently reported attempts to bond endothelial cell 
growth factor (ECGF) to biomaterials. Heparin-bonded biomaterials have been 
available for several years. It is of interest that fibronectin binds heparin as well. 
Heparin has been shown to be synergistic with ECGF in promoting EC growth:' and 
in addition inhibits smooth muscle cell proliferation.46 Smooth muscle growth in the 
body of grafts may be of little consequence, but it has been implicated in the 
development of anastomotic intimal hyperplasia (IH), said to be the cause of late 
failure in small diameter grafts. Why IH occurs is not known, but it has been suggested 
that platelet adhesion with subsequent release of platelet-derived growth factor 
(PDGF) stimulates the smooth muscle to proliferate. Antiplatelet drugs have been 
reported to decrease IH in experimental animals, but their efficacy in man remains to 
be proved.47 It is clear that antiplatelet drugs are necessary to maintain patency in 
small diameter grafts in the short term." Aspirin and dipyridamole have been the most 
commonly used, but other cyclooxygenase and thromboxane synthetase inhibitors have 
been used as well. The most effective appears to be aspirin alone, although the reasons 
are ~nclear:~*~ Whether the rapid endothelialization of grafts by seeding will reduce 
IH has not been proved. It has been shown that EC continue to turn over and smooth 
muscle cells continue to proliferate at anastomoses even after grafts are healed.'' It has 
been suggested that this is due to chronic EC injury. It has been shown that smooth 
muscle cells secrete growth factors acting on neighboring smooth muscle cells and that 
normal EC produce a heparin-like inhibitor of smooth muscle proliferati~n.'~ It has 
been suggested that injured EC may be incapable of secreting this inhibitor, and the 
result is 
It is clear that EC seeding has dramatically improved small diameter graft patency 
in both animals'* and man' in the short term. Whether it will improve the long-term 
failure rate is unknown at this point. In the long run the solution to small vessel grafting 
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will most likely be a combination of better grafts, enhancement of healing by seeding or 
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